Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | SOD1 | P00441 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2340414 | 1.00 | NPSR1 (0.33) | NPSR1MAPTMEN1POLBKMT2A | |
| SCHEMBL17064244 | 1.00 | NPSR1 (0.33) | NPSR1MAPTMEN1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL17062254 | 0.98 | NPSR1 (0.32) | NPSR1MAPTMEN1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL17064251 | 0.98 | NPSR1 (0.32) | NPSR1MAPTMEN1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL17062207 | 0.98 | NPSR1 (0.32) | NPSR1MAPTMEN1POLBKMT2A | |
| SCHEMBL22838077 | 0.89 | NPSR1 (0.35) | NPSR1MAPTMEN1POLBKMT2A | |
| SCHEMBL18629006 | 0.89 | NPSR1 (0.35) | NPSR1MAPTMEN1POLBKMT2A | |
| SCHEMBL9043242 | 0.88 | FFAR3 (0.36) | NPSR1MAPTMEN1KMT2ALMNA | |
| SCHEMBL13240707 | 0.88 | FFAR3 (0.36) | NPSR1MAPTMEN1KMT2ALMNA | |
| SCHEMBL13240708 | 0.88 | FFAR3 (0.36) | NPSR1MAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3114128-A1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015132276-A1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-11 | — | — | WO | disclosed |
| CN-102762102-A | Novel oxadiazole compounds | ABBOTT LAB | 2012-10-31 | — | — | CN | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | S1PR3, S1PR1, S1PR2 | NPSR1 472/4885MAPT 4556/4885MEN1 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.